Related Experiment Videos
Lymphoma immunophenotyping: "borderline" lymphomas.
Delia Mut-Popescu1, Anca Lupu, H. Bumbea
1Department of Hematology, "Coltea" Clinical Hospital, "Carol Davila" University of Medicine, 1, I.C. Bratianu Blvd., 70453 Bucharest, Romania. teammut@cmb.ro
Journal of Cellular and Molecular Medicine
|August 9, 2002
Summary
Distinguishing between chronic lymphocytic leukemia and mantle cell lymphoma requires careful immunophenotyping. Some CD19(+) CD5(+) B-cell disorders present borderline features, suggesting an intermediate neoplastic grade.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Accurate immunophenotyping is crucial for diagnosing B-cell lymphoproliferative disorders.
- Distinguishing between chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is critical due to differing prognoses and treatment strategies.
- CD19(+) CD5(+) B-lymphocyte disorders present diagnostic challenges.
Purpose of the Study:
- To investigate the immunophenotypic characteristics of CD19(+) CD5(+) B-cell lymphoproliferative disorders.
- To identify cases that do not fit established diagnostic criteria for CLL or MCL.
- To propose a classification for "borderline" CD19(+) CD5(+) B-cell lymphoproliferative disorders.
Main Methods:
- Flow cytometry analysis of peripheral blood B-lymphocytes.
- Evaluation of CD19, CD5, and CD23 expression.
- Assessment of FMC7 and surface immunoglobulin (sIg) expression.
Main Results:
- Identified CD19(+) CD5(+) lymphoproliferative disorders lacking definitive CLL or MCL criteria.
- Observed cases with low/absent CD23 expression, negative FMC7, and absent sIg.
- These cases represent a distinct group with intermediate neoplastic grade.
Conclusions:
- Some CD19(+) CD5(+) B-cell lymphoproliferative disorders present "borderline" features.
- These borderline cases may represent an intermediate neoplastic grade, distinct from CLL and MCL.
- Further research is needed to fully characterize and manage these intermediate-grade disorders.